



an Open Access Journal by MDPI

Advanced Biomedical Research on COVID-19

Guest Editor:

Dr. Federica Perelli

Azienda USL Toscana Centro,
Gynecology and Obstetric
Department, Santa Maria
Annunziata Hospital, 50012
Florence, Italy

Deadline for manuscript
submissions:

closed (29 February 2024)

Message from the Guest Editor

Dear Colleagues,

SARS-Cov-2 has rapidly spread in the world, with a significant unexplainable difference between different countries. The real-time polymerase chain reaction (RT-PCR) on nasopharyngeal swab was the most widely used test to detect the virus but also antibody testing shows specific IgG/IgM against SARSCoV-2. Although the pathogen SARS-CoV-2 is highly contagious, neonates born to women with asymptomatic or symptomatic COVID-19 are rarely infected by the virus. This special issue aims to implement the present knowledge about diagnostic, prognostic and therapeutic novelties, aimed at the best management of the COVID-19. Research on maternal-fetal antibody status and on obstetric outcomes of COVID-19 during pregnancy are encouraged.

Dr. Federica Perelli
Guest Editor



mdpi.com/si/146754

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI